Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-300-3 | CAS number: 56-93-9
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
Benzyltrimethylammonium chloride was examined in two Ames tests, an in vitro chromosomal aberration study using Chinese Hamster lung fibroblasts (V79), and in vitro CHO/HPRTassay as well as an in vivo chromosomal aberration study, i.e., mouse micronucleus study following dosing of mice for 13 weeks.
Benzyltrimethylammonium chloride was not mutagenic in Salmonella typhimurium strains TA97, TA98, TA100, and TA1535, with or without S9 metabolic activation enzymes. The test material, Benzyltrimethylammonium chloride, did not induce gene mutations in the S. typhimurium TA98, Ta100, TA1535 and TA1537 and E. coli WP2 strains. The ability of benzyltrimethylammoniumchloride to cause chromosome aberrations was examined using Chinese hamster lung cells. This chemical slightly increased incidences of structural chromosomal aberrations with an exogeneous metabolic activation system. Clear reproducibility was obtained the confirmation study. Benzyltrimethylammonium chloride (BTMAC) was negative in the In Vitro Mammalian Cell Forward Gene Mutation (CHO/HPRT) Assay with Duplicate Cultures under the conditions, and according to the criteria, of the test protocol. Significant increases in the frequency of micronucleated normochromatic erythrocytes were found in the peripheral blood of male and female mice administered benzyltrimethylammonium chloride by gavage for 13 weeks
Endpoint Conclusion: Adverse effect observed (positive)
Justification for classification or non-classification
Meets critera for classification as Category 2.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
